|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|---|---|---|
| Net profit / (loss) (-) | |||||
| Increase in provisions | |||||
| Impairment of the cell therapy business | |||||
| Adjustment for non-cash transactions | |||||
| Adjustment for items to disclose separately under operating cash flow | |||||
| Adjustment for items to disclose under investing and financing cash flows | |||||
| Change in working capital other than deferred income | |||||
| cash used for other liabilities related to the disposal of subsidiaries | |||||
| Decrease in deferred income | |||||
| Cash used in operations | |||||
| Interest paid | |||||
| Interest received | |||||
| Income taxes paid | |||||
| Net cash flows used in operating activities | |||||
| Purchase of property, plant and equipment | |||||
| Purchase of and expenditure in intangible fixed assets | |||||
| Proceeds from disposal of property, plant and equipment | |||||
| Purchase of financial investments | |||||
| Investment income received related to current financial investments | |||||
| Sale of current financial investments | |||||
| Proceeds from settlement of hedging instrument | |||||
| Cash out from disposal of subsidiaries, net of cash disposed of | |||||
| Cash advances and loans to third parties | |||||
| Acquisition of financial assets held at fair value through profit or loss | |||||
| Acquisition of financial assets held at fair value | |||||
| Net cash flows generated from/used in (-) investing activities | |||||
| Payment of lease liabilities and other debts | |||||
| Proceeds from capital and share premium increases from exercise of subscription rights | |||||
| Net cash flows used in financing activities | |||||
| Increase/decrease (-) in cash and cash equivalents | |||||
| Cash and cash equivalents at beginning of year | |||||
| Effect of exchange rate differences on cash and cash equivalents | |||||
| Cash and cash equivalents at end of year | |||||
Loading...